Pressmeddelande -
Scandinavian Biopharma expands its product portfolio with an immunosuppressive drug
Scandinavian Biopharma recently entered into a distribution agreement with Neovii Pharmaceuticals AG, a fully integrated global biopharmaceutical organization based in Switzerland, and has expanded its product offering to include Neovii’s GRAFALON®.
“With GRAFALON® we offer an immunosuppressive drug with a proven track record that is well established in the hospital market. This product is unique since it is registered for use in both organ and stem-cell transplantation”, says Björn Sjöstrand, CEO at Scandinavian Biopharma. In solid organ transplantation, GRAFALON® can help prevent organ rejection or suppress active rejection. In stem cell transplantation, it is used to suppress the reaction of the transplanted cells against the patient´s own cell (graft-versus-host disease or GvHD).
GRAFALON® is a polyclonal antibody that contains a combination of different antibodies targeting multiple pathways of disease. It is therefore used to suppress immune reactions leading to organ rejection or GvHD.
“By adding GRAFALON® we strength our offering to transplantation centers in Sweden and we will accelerate our growth in the distribution business even further”, says Björn Sjöstrand.”
For more information, please contact: Björn Sjöstrand, CEO: +46 727-125 120, bjorn.sjostrand@scandinavianbiopharma.se
Ämnen
Scandinavian Biopharma
Scandinavian Biopharma is a Swedish research-based biotech company. The company is also a leading distributor of vaccines and immunoglobulins to the Nordic market. We are developing, together with PATH and researchers at the University of Gothenburg, a new oral travelers’ diarrhea vaccine candidate against ETEC. In several clinical trials, the vaccine has been proven safe and has shown a strong ability to activate the immune system. We believe that PATH’s support of this work to develop a new vaccine for diarrheal disease confirms that we are on the right path, that our vaccine meets very high standards, and that it has the potential to save lives in the developing world.
